Taletrectinib (Ibtrozi) is a newly FDA-approved treatment for ROS1-positive non-small cell lung cancer (NSCLC), a rare subtype driven by ROS1 gene rearrangements. These fusions promote tumor growth, making them highly responsive to targeted therapy.
Taletrectinib is a next-generation oral ROS1 inhibitor with high potency, selectivity, and the ability to cross the blood-brain barrier. It works against resistance mutations and effectively treats brain metastases, making it suitable for both treatment-naïve patients and those who have progressed on prior ROS1 TKIs.
Clinical trials showed impressive results, with objective response rates over 85% in newly diagnosed patients and over 50% in pretreated patients. Side effects are generally manageable, mainly mild gastrointestinal issues and liver enzyme elevations. Taletrectinib offers a powerful, well-tolerated option for ROS1-positive NSCLC, including cases with CNS involvement, and represents a major advance for this rare lung cancer subtype.